The Role of H3K4me3 in Transcriptional Regulation Is Altered in Huntington's Disease

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2015 Dec 5

PMID 26636336

Citations 27

Authors

Xianjun Dong

Junko Tsuji

Adam Labadorf

Panos Roussos

Jiang-Fan Chen

Richard H Myers

Schahram Akbarian

Zhiping Weng

Affiliations

Soon will be listed here.

Abstract

Huntington's disease (HD) is an autosomal-dominant neurodegenerative disorder resulting from expansion of CAG repeats in the Huntingtin (HTT) gene. Previous studies have shown mutant HTT can alter expression of genes associated with dysregulated epigenetic modifications. One of the most widely studied chromatin modifications is trimethylated lysine 4 of histone 3 (H3K4me3). Here, we conducted the first comprehensive study of H3K4me3 ChIP-sequencing in neuronal chromatin from the prefrontal cortex of six HD cases and six non-neurologic controls, and its association with gene expression measured by RNA-sequencing. We detected 2,830 differentially enriched H3K4me3 peaks between HD and controls, with 55% of them down-regulated in HD. Although H3K4me3 signals are expected to be associated with mRNA levels, we found an unexpected discordance between altered H3K4me3 peaks and mRNA levels. Gene ontology (GO) term enrichment analysis of the genes with differential H3K4me3 peaks, revealed statistically significantly enriched GO terms only in the genes with down-regulated signals in HD. The most frequently implicated biological process terms are organ morphogenesis and positive regulation of gene expression. More than 9,000 H3K4me3 peaks were located not near any recognized transcription start sites and approximately 36% of these "distal" peaks co-localized to known enhancer sites. Six transcription factors and chromatin remodelers are differentially enriched in HD H3K4me3 distal peaks, including EZH2 and SUZ12, two core subunits of the polycomb repressive complex 2 (PRC2). Moreover, PRC2 repressive state was significantly depleted in HD-enriched peaks, suggesting the epigenetic role of PRC2 inhibition associated with up-regulated H3K4me3 in Huntington's disease. In summary, our study provides new insights into transcriptional dysregulation of Huntington's disease by analyzing the differentiation of H3K4me3 enrichment.

Citing Articles

The Promise of Epigenetic Editing for Treating Brain Disorders.

Gonzalez Molina L, Dolga A, Rots M, Sarno F Subcell Biochem. 2025; 108():111-190.

PMID: 39820862 DOI: 10.1007/978-3-031-75980-2_4.

Lineage specific 3D genome structure in the adult human brain and neurodevelopmental changes in the chromatin interactome.

Rahman S, Dong P, Apontes P, Fernando M, Kosoy R, Townsley K Nucleic Acids Res. 2023; 51(20):11142-11161.

PMID: 37811875 PMC: 10639075. DOI: 10.1093/nar/gkad798.

Involvement of the H3.3 Histone Variant in the Epigenetic Regulation of Gene Expression in the Nervous System, in Both Physiological and Pathological Conditions.

Di Liegro C, Schiera G, Schiro G, Di Liegro I Int J Mol Sci. 2023; 24(13).

PMID: 37446205 PMC: 10342106. DOI: 10.3390/ijms241311028.

Transcriptional and Histone Acetylation Changes Associated with CRE Elements Expose Key Factors Governing the Regulatory Circuit in the Early Stage of Huntington's Disease Models.

Arancibia-Opazo S, Contreras-Riquelme J, Sanchez M, Cisternas-Olmedo M, Vidal R, Martin A Int J Mol Sci. 2023; 24(13).

PMID: 37446028 PMC: 10341483. DOI: 10.3390/ijms241310848.

Cerebellar granule neurons induce Cyclin D1 before the onset of motor symptoms in Huntington's disease mice.

Bauer S, Chen C, Jonson M, Kaczmarczyk L, Magadi S, Jackson W Acta Neuropathol Commun. 2023; 11(1):17.

PMID: 36670467 PMC: 9854201. DOI: 10.1186/s40478-022-01500-x.

References

Li C, Hung Wong W . Model-based analysis of oligonucleotide arrays: model validation, design issues and standard error application. Genome Biol. 2001; 2(8):RESEARCH0032. PMC: 55329. DOI: 10.1186/gb-2001-2-8-research0032. View

Steffan J, Bodai L, PALLOS J, Poelman M, McCampbell A, Apostol B . Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila. Nature. 2001; 413(6857):739-43. DOI: 10.1038/35099568. View

Milavetz B . SP1 and AP-1 elements direct chromatin remodeling in SV40 chromosomes during the first 6 hours of infection. Virology. 2002; 294(1):170-9. DOI: 10.1006/viro.2001.1308. View

Kent W, Sugnet C, Furey T, Roskin K, Pringle T, Zahler A . The human genome browser at UCSC. Genome Res. 2002; 12(6):996-1006. PMC: 186604. DOI: 10.1101/gr.229102. View

Dunah A, Jeong H, Griffin A, Kim Y, Standaert D, Hersch S . Sp1 and TAFII130 transcriptional activity disrupted in early Huntington's disease. Science. 2002; 296(5576):2238-43. DOI: 10.1126/science.1072613. View

Duyao M, Ambrose C, Myers R, Novelletto A, Persichetti F, Frontali M . Trinucleotide repeat length instability and age of onset in Huntington's disease. Nat Genet. 1993; 4(4):387-92. DOI: 10.1038/ng0893-387. View

Myers R, Macdonald M, Koroshetz W, Duyao M, Ambrose C, Taylor S . De novo expansion of a (CAG)n repeat in sporadic Huntington's disease. Nat Genet. 1993; 5(2):168-73. DOI: 10.1038/ng1093-168. View

Flanagan J, Vanderhaeghen P . The ephrins and Eph receptors in neural development. Annu Rev Neurosci. 1998; 21:309-45. DOI: 10.1146/annurev.neuro.21.1.309. View

Bernstein B, Kamal M, Lindblad-Toh K, Bekiranov S, Bailey D, Huebert D . Genomic maps and comparative analysis of histone modifications in human and mouse. Cell. 2005; 120(2):169-81. DOI: 10.1016/j.cell.2005.01.001. View

10.

Kim T, Barrera L, Qu C, Van Calcar S, Trinklein N, Cooper S . Direct isolation and identification of promoters in the human genome. Genome Res. 2005; 15(6):830-9. PMC: 1142473. DOI: 10.1101/gr.3430605. View

11.

Myers R . Huntington's disease genetics. NeuroRx. 2005; 1(2):255-62. PMC: 534940. DOI: 10.1602/neurorx.1.2.255. View

12.

Kim T, Barrera L, Zheng M, Qu C, Singer M, Richmond T . A high-resolution map of active promoters in the human genome. Nature. 2005; 436(7052):876-80. PMC: 1895599. DOI: 10.1038/nature03877. View

13.

Cattaneo E, Zuccato C, Tartari M . Normal huntingtin function: an alternative approach to Huntington's disease. Nat Rev Neurosci. 2005; 6(12):919-30. DOI: 10.1038/nrn1806. View

14.

Connor C, Cheung I, Simon A, Jakovcevski M, Weng Z, Akbarian S . A simple method for improving the specificity of anti-methyl histone antibodies. Epigenetics. 2010; 5(5):392-5. DOI: 10.4161/epi.5.5.11874. View

15.

Santos-Rosa H, Schneider R, Bannister A, Sherriff J, Bernstein B, Emre N . Active genes are tri-methylated at K4 of histone H3. Nature. 2002; 419(6905):407-11. DOI: 10.1038/nature01080. View

16.

Sugars K, Rubinsztein D . Transcriptional abnormalities in Huntington disease. Trends Genet. 2003; 19(5):233-8. DOI: 10.1016/S0168-9525(03)00074-X. View

17.

Ruthenburg A, Allis C, Wysocka J . Methylation of lysine 4 on histone H3: intricacy of writing and reading a single epigenetic mark. Mol Cell. 2007; 25(1):15-30. DOI: 10.1016/j.molcel.2006.12.014. View

18.

Heintzman N, Stuart R, Hon G, Fu Y, Ching C, Hawkins R . Distinct and predictive chromatin signatures of transcriptional promoters and enhancers in the human genome. Nat Genet. 2007; 39(3):311-8. DOI: 10.1038/ng1966. View

19.

Sadri-Vakili G, Bouzou B, Benn C, Kim M, Chawla P, Overland R . Histones associated with downregulated genes are hypo-acetylated in Huntington's disease models. Hum Mol Genet. 2007; 16(11):1293-306. DOI: 10.1093/hmg/ddm078. View

20.

Barski A, Cuddapah S, Cui K, Roh T, Schones D, Wang Z . High-resolution profiling of histone methylations in the human genome. Cell. 2007; 129(4):823-37. DOI: 10.1016/j.cell.2007.05.009. View